Core Viewpoint - Nuwellis is conducting a conference call to discuss its financial results for the third quarter of 2025, highlighting the importance of the information shared during the call [2][3]. Financial Results - The financial results for the third quarter ended September 30, 2025, were released earlier, and details can be found on the company's Investor page [3]. Leadership - The call features key executives including John Erb, Chairman of the Board and CEO, and Lynn Blake, the Interim Head of Finance [2].

Financial Performance - Revenue for Q3 2025 was $1602 million, a 1% increase compared to Q3 2024[13] - Adjusted EBITDA for Q3 2025 was $518 million, with a 323% Adjusted EBITDA margin[13] - Adjusted diluted EPS for Q3 2025 was $101, compared to $087 in Q3 2024, a 16% increase[13] - The full-year revenue range is revised to $6200 million - $6250 million, with an Adjusted EBITDA margin guidance revised to approximately 310%[13] - Free Cash Flow before one-time costs YTD September 2025 was $813 million, compared to $693 million in 2024[32] Revenue Analysis by Segment - Total Women's Health revenue was $429 million in Q3 2025, a decrease of 3% compared to Q3 2024[17] However, year-to-date Women's Health revenue increased by 3% to $1354 million[15,17] - Nexplanon revenue was $223 million in Q3 2025, a decrease of 8% compared to Q3 2024[17] - Total Biosimilars revenue was $196 million in Q3 2025, a 19% increase compared to Q3 2024[20] Year-to-date Biosimilars revenue increased by 2% to $510 million[20] - Hadlima revenue increased by 57% to $63 million in Q3 2025[20] - Total Established Brands revenue was $956 million in Q3 2025, a 1% increase compared to Q3 2024[24] Year-to-date Established Brands revenue decreased by 5% to $2778 million[24] Geographic Performance - United States revenue increased by 2% to $406 million in Q3 2025[56] - Europe and Canada revenue decreased by 4% to $417 million in Q3 2025[56] - Latin America, Middle East, Russia and Africa revenue increased by 18% to $286 million in Q3 2025[56] Guidance - Full-year revenue guidance is revised to $6200 million - $6250 million, representing a nominal revenue growth of (32%) - (24%)[39] - Adjusted EBITDA margin guidance is revised to approximately 310%[39]

Core Points - The conference call is focused on Haleon's third quarter trading statement for 2025 [1] - Jo Russell, Head of Investor Relations, and Dawn Allen, CFO, are leading the discussion [1] Company Overview - The company is expected to provide forward-looking statements regarding estimates, plans, and expectations during the call [2] - Listeners are reminded to refer to the company's announcements and filings for more details on potential discrepancies in actual results [2] Q&A Session - After the remarks from the CFO, a question-and-answer session will be held for participants [3] - Dial-in details for the webcast audience are provided in the press release [3]

PresentationI now would like to turn the conference over to Jean-François Boucher, ADF Group's Chief Financial Officer. Please go ahead, sir.Good morning, ladies and gentlemen, and welcome to the ADF Group Inc. Presentation for Acquisition of LAR Groupe. [Operator Instructions] Also note that this call is being recorded on Wednesday, October 29, 2025.Jean-François BoursierChief Financial Officer Thank you. Good morning, and welcome to ADF's conference call, where we will provide additional information about ...

Chemed Corporation Overview - Chemed's Adjusted EBITDA margin was 20% in 2023[10, 18] - Chemed's Adjusted net income increased 13.8% from 2023 to 2024[10, 18] - Chemed's Adjusted diluted EPS from continuing operations increased 13.9% from 2023 to 2024[10, 18] Roto-Rooter - Roto-Rooter's service revenues and sales decreased by 5.2% from 2023 to 2024[10] - Roto-Rooter's adjusted net income decreased by 13.5% from 2023 to 2024[10] - Roto-Rooter's service revenues and sales were $900309 thousand in 2024[36] - Roto-Rooter's Adjusted EBITDA was $237087 thousand in 2024[36] VITAS Healthcare - VITAS's service revenues and sales increased by 16.4% from 2023 to 2024[10] - VITAS's adjusted net income increased by 38.9% from 2023 to 2024[10] - VITAS's revenues were $408 million in Q3 2025[47] - VITAS's net service revenue was $1530978 thousand in 2024[78]

Financial Performance - Q3 2025 - Revenue reached $70.005 million[11], consistent across both GAAP and Non-GAAP measures[11] - GAAP gross profit was $32.040 million with a gross margin of 46%[11] - Non-GAAP gross profit was $33.636 million with a gross margin of 48%[11] - GAAP operating loss was $(2.344) million, while Non-GAAP operating income was $3.123 million[11] - Cash balance decreased to $4.109 million from $11.125 million in the previous quarter[11] Outlook and Future Goals - Q4 2025 revenue is projected to be $83.3 million, setting a new record[41] - Operating profit is expected to increase to $3.5 million in Q4 2025, also a record[41] - SunPower aims to grow from $300 million in 2025 to $1 billion in 2028[42] - The company's vision is to be recognized as No 1 in solar through advanced technology[43] Strategic Initiatives - SunPower signed a joint development agreement with REC[39] - The company received a 200,000 battery opportunity through partner Enphase[40] - Includes 19 current employees from Sunder[18]

Core Points - Delcath Systems held a Business Update Call to discuss recent developments and future plans [2] - Key executives present included the CEO, CFO, and Chief Medical Officer, indicating a comprehensive leadership overview [2] Company Overview - The call was hosted by David Hoffman, who serves as General Counsel, Corporate Secretary, and Chief Compliance Officer [2] - A prerecorded conversation featuring Dr. Vincent T. Ma, an Assistant Professor and Medical Oncologist, was included to provide expert insights [2] Forward-Looking Statements - The company issued a safe harbor statement regarding forward-looking statements, emphasizing that expectations and assumptions are based on reasonable beliefs but are not guaranteed [3]

Group 1 - Aclaris held its 2025 R&D Day in New York, indicating a focus on research and development initiatives [1] - The event was attended by both in-person participants and those joining via webcast, highlighting the company's commitment to stakeholder engagement [1] - The presentation included forward-looking statements, which are subject to risks and uncertainties that may affect actual results [2]

Core Points - BASF and Carlyle announced a Coatings Transaction, which is the primary focus of the conference call [1][2] - The call is structured to first address questions from financial market participants, followed by questions from media attendees [1][2] - The conference call is being recorded for transparency and future reference [2] Company and Industry Summary - The conference call is specifically limited to discussions regarding the Coatings Transaction, indicating a focused approach to investor relations [2] - Forward-looking statements were made during the presentation, highlighting the reliance on current estimates and projections from the Board of Executive Directors [3] - The company acknowledges that forward-looking statements involve risks and uncertainties, which may affect the accuracy of the assumptions made [3]

Core Viewpoint - Ovid Therapeutics is conducting a data call to discuss the Top Line OV329 Phase I readout, indicating progress in their clinical development efforts [2]. Group 1: Company Overview - The call is hosted by Victoria Fort, Senior Vice President of Corporate Affairs and Corporate Strategy, along with key executives including Dr. Jeremy Levin, Meg Alexander, Jeff Rona, and Zhong Zhong [2]. Group 2: Forward-Looking Statements - The company will be making forward-looking statements during the call, which are subject to risks and uncertainties that could lead to actual results differing from expectations [3].